Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP TMS S.A. Adds Global Distribution of LMA StoneBreaker(TM) System
EDAP Adds Malaysia, Korea to France as Exclusive Markets and Secures Worldwide Exclusivity When StoneBreaker™ Offered with EDAP's Devices
View HTML
Toggle Summary New Ablatherm®-HIFU Site Launched in the United Kingdom
First UK Fixed Revenue-Per-Procedure Service Available at Capio Springfield Hospital
View HTML
Toggle Summary EDAP Ablatherm-HIFU Strongly Highlighted in European Congresses
EDAP Ablatherm-HIFU Strongly Highlighted in European Congresses LYON, France , June 18 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports continued and sustained marketing presence in various
View HTML
Toggle Summary EDAP to Add University of Colorado Under Direction of Dr. David Crawford to Clinical Study
EDAP to Add University of Colorado Under Direction of Dr. David Crawford to Clinical Study LYON, France , June 5 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, intends to add the University of
View HTML
Toggle Summary EDAP Looking to Accelerate US Study Enrollment With the Upcoming Addition of McMaster University Hospital
EDAP Looking to Accelerate US Study Enrollment With the Upcoming Addition of McMaster University Hospital LYON, France , June 1 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports further
View HTML
Toggle Summary EDAP Ablatherm-HIFU Presents at American Urology Association Accelerates US Study Enrollment
EDAP Ablatherm-HIFU Presents at American Urology Association Accelerates US Study Enrollment LYON, France , May 23 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports the continuing advancement
View HTML
Toggle Summary EDAP Fast-Tracks U.S. Clinical Trial for Non-Invasive Prostate Cancer
Long-Term European Results Highlight the Importance of This Study for U.S.
View HTML
Toggle Summary Ablatherm-HIFU Adoption Growing Across Europe
European Marketing and Education Strategy Validated
View HTML
Toggle Summary EDAP TMS S.A. Reports 2007 First Quarter Results; Ablatherm-HIFU Treatments Grow
European RPP Program on Target for 2008 Profitability; FDA Trial Launch Positions EDAP for Direct USA Control; EDAP, China Medical Alliance Unites HIFU Leaders
View HTML
Toggle Summary Ablatherm-HIFU Localized Prostate Cancer Clinical Study Resumes at Virginia Urology Center
EDAP to Accelerate Treatment Rates at Study Centers
View HTML